Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Preferred Shares (2016 - 2025)

Historic Preferred Shares for Guided Therapeutics (GTHP) over the last 13 years, with Q3 2025 value amounting to $817000.0.

  • Guided Therapeutics' Preferred Shares fell 250.6% to $817000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $817000.0, marking a year-over-year decrease of 250.6%. This contributed to the annual value of $834000.0 for FY2024, which is 47.73% down from last year.
  • As of Q3 2025, Guided Therapeutics' Preferred Shares stood at $817000.0, which was down 250.6% from $834000.0 recorded in Q2 2025.
  • Over the past 5 years, Guided Therapeutics' Preferred Shares peaked at $3.0 million during Q2 2021, and registered a low of $817000.0 during Q3 2025.
  • Its 5-year average for Preferred Shares is $1.4 million, with a median of $838000.0 in 2023.
  • Its Preferred Shares has fluctuated over the past 5 years, first soared by 24736.23% in 2021, then plummeted by 7104.29% in 2023.
  • Over the past 5 years, Guided Therapeutics' Preferred Shares (Quarter) stood at $3.0 million in 2021, then plummeted by 70.29% to $880000.0 in 2022, then decreased by 4.77% to $838000.0 in 2023, then dropped by 0.48% to $834000.0 in 2024, then fell by 2.04% to $817000.0 in 2025.
  • Its Preferred Shares was $817000.0 in Q3 2025, compared to $834000.0 in Q2 2025 and $834000.0 in Q1 2025.